Allergy Therapeutics

Latest Headlines

Latest Headlines

Allergy Therapeutics scores $30M to finish grass allergy vaccine

After a damaging delay back in 2007, Worthing, U.K.-based Allergy Therapeutics is attempting to revive its Pollinex Quattro Grass allergy vaccine. And now, it has some new funding to help it do just that.

Allergy Therapeutics raises £20M to bounce back from 5-year clinical hold

Allergy Therapeutics has turned to public investors for £20 million ($30 million) to move its subcutaneous immunotherapy allergy vaccine through late-phase development. The cash will fund Allergy Therapeutics' attempt to bounce back from the 5-year clinical hold of its U.S. trial program.

FDA lifts hold on Allergy Therapeutics' grass pollen allergy vax

Allergy Therapeutics will court a partner to market its Pollinex Quattro Grass vaccine now that the FDA lifted a clinical hold on the grass pollen allergy shot.

UPDATED: Cytos revives lead program in $40M financing deal with Amgen, venBio

Swiss biotech Cytos has scraped together $40 million to advance its pipeline of immunotherapies, giving itself much-needed capital after a cash crunch last summer forced the company to ax most of its staff.

Allergan buys Serica Tech

Allergan revealed that it acquired Serica Technologies at the end of last year. Allergan, which makes Botox, plans to operate the company as a subsidiary in Medford, MA. The company makes biomaterial

Allergy Therapeutics advances ragweed vax

Allergy Therapeutics was forced to halt its Phase III trial of its Pollinex Quattro ragweed vaccine, but researchers for the company say the data still demonstrates its effectiveness. The study had

Allergy Therapeutics shares spike on late-stage data

Shares of the UK's Allergy Therapeutics surged on the news that its experimental hay fever vaccine--Pollinex Quattro--demonstrated positive results in a crucial Phase III study, which they say was

Allergy Therapeutics afflicted by FDA's move to halt trials

Shares of Allergy Therapeutics tumbled 22 percent after the FDA froze two late-stage studies of a hayfever vaccine after one of the volunteers in a trial fell ill. The patient reported neurological

Allergy vaccine posts positive pivotal data

London-based Allergy Therapeutics' ragweed allergy vaccine passed a pivotal clinical trial. Researchers said that Pollinex Quattro Ragweed demonstrated significant improvements in symptoms compared